Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022. https://doi.org/10.1016/s2468-1253(22)00165-0

Article  PubMed  Google Scholar 

Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024. https://doi.org/10.1136/gutjnl-2023-330595

Article  PubMed  Google Scholar 

Tacke F, Horn P, Wai-Sun Wong V, et al. EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. https://doi.org/10.1016/j.jhep.2024.04.031

Article  CAS  Google Scholar 

Fan JG, Xu XY, Yang RX, et al. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (Version 2024). J Clin Transl Hepatol. 2024. https://doi.org/10.14218/jcth.2024.00311

Article  PubMed  PubMed Central  Google Scholar 

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5. https://doi.org/10.1053/j.gastro.2015.04.005

Article  PubMed  Google Scholar 

Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity (Silver Spring). 2024. https://doi.org/10.1002/oby.24027

Article  PubMed  Google Scholar 

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. https://doi.org/10.1056/NEJMoa2301972

Article  CAS  PubMed  Google Scholar 

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. https://doi.org/10.1056/NEJMoa1603827

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3

Article  CAS  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. https://doi.org/10.1056/NEJMoa2307563

Article  CAS  PubMed  Google Scholar 

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–1084. https://doi.org/10.1056/NEJMoa2306963

Article  CAS  PubMed  Google Scholar 

Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394–1407. https://doi.org/10.1056/NEJMoa2313917

Article  CAS  PubMed  Google Scholar 

Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018. https://doi.org/10.1016/s2213-8587(18)30024-x

Article  PubMed  Google Scholar 

Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–121. https://doi.org/10.1056/NEJMoa2403347

Article  CAS  PubMed  Google Scholar 

Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2403664

Article  PubMed  Google Scholar 

Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193–1205. https://doi.org/10.1056/NEJMoa2404881

Article  CAS  PubMed  Google Scholar 

Meissner WG, Remy P, Giordana C, et al. Trial of lixisenatide in early parkinson’s disease. N Engl J Med. 2024;390(13):1176–1185. https://doi.org/10.1056/NEJMoa2312323

Article  CAS  PubMed  Google Scholar 

Anson M, Henney AE, Broadwell N, et al. Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. eClinicalMedicine. 2024. https://doi.org/10.1016/j.eclinm.2024.102777

Article  PubMed  PubMed Central  Google Scholar 

Sorli C, Harashima S-i, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1) a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017. https://doi.org/10.1016/S2213-8587(17)30013-X

Article  PubMed  Google Scholar 

Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017. https://doi.org/10.1016/s2213-8587(17)30092-x

Article  PubMed  Google Scholar 

Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label. Randomized Clin Trial Diabetes Care. 2017;41(2):258–266. https://doi.org/10.2337/dc17-0417

Article  CAS  Google Scholar 

Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366. https://doi.org/10.1016/S2213-8587(17)30085-2

Article  CAS  PubMed  Google Scholar 

Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized. Controlled Trial J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-00070

Article  PubMed  Google Scholar 

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141

Article  CAS  PubMed  Google Scholar 

Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–1732. https://doi.org/10.2337/dc19-0749

Article  CAS  PubMed  Google Scholar 

Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019. https://doi.org/10.2337/dc19-0883

Article  PubMed  PubMed Central  Google Scholar 

Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019. https://doi.org/10.1001/jama.2019.2942

Article  PubMed  PubMed Central  Google Scholar 

Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019. https://doi.org/10.1016/s0140-6736(19)31271-1

Article  PubMed  Google Scholar 

Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019. https://doi.org/10.1016/s2213-8587(19)30192-5

Article  PubMed